The field of action of regenerative medicine (RM) is growing daily. Indeed, we only have to look at the economic figures that it moves, with an estimated market value for 2020 of 61,000 million Euros.
However, RM also has important ethical components, not only related with the use of embryonic stem cells — cells which, as we know, require the destruction of human embryos to obtain them — but also because these practices in many cases entail ethical aspects that must be carefully evaluated.
Regenerative medicine today
Given the ethical aspect of the use of RM (regenerative medicine ethics), we believe it interesting to review its present clinical use, since both facets of these treatments go hand in hand.
In relation to the medical aspect of RM, Spanish medical website Diario Médico (see HERE) published a fascinating article, from which we have extracted some paragraphs.
The most noteworthy part of the article, in our opinion, is the summary of the possible uses of cell therapy. In it, it states how this type of cell therapy has already been used in very different diseases, which is undoubtedly a ray of hope for patients who suffer them.
It is also worth noting how most of the companies involved in this market are from the United States, although there are others from Japan and China, which are not mentioned in this Report.
Cell therapy is the aspect that seems to be more widely accepted. Although the report does not refer to it specifically, the best prospects within this field are focused on the use of reprogrammed adult cells (iPS) and mesenchymal stem cells.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.